Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$1.05 USD
+0.09 (9.40%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for Gossamer Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 296 | 256 | 325 | 513 | 402 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 6 | 7 | 9 | 7 |
Total Current Assets | 307 | 262 | 332 | 522 | 409 |
Net Property & Equipment | 2 | 4 | 5 | 6 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 2 |
Total Assets | 312 | 272 | 344 | 539 | 427 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 1 | 3 | 8 | 1 |
Current Portion Long-Term Debt | 12 | 12 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 34 | 36 | 37 | 31 | 36 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 52 | 49 | 40 | 39 | 37 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 197 | 196 | 150 | 144 | 0 |
Long-Term Debt | 1 | 12 | 29 | 29 | 28 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 249 | 260 | 222 | 219 | 74 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,275 | 1,045 | 933 | 898 | 686 |
Retained Earnings | -1,212 | -1,032 | -812 | -578 | -334 |
Other Equity | 0 | -1 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 63 | 12 | 121 | 321 | 352 |
Total Liabilities & Shareholder's Equity | 312 | 272 | 344 | 539 | 427 |
Total Common Equity | 63 | 12 | 121 | 321 | 352 |
Shares Outstanding | 225.40 | 94.40 | 76.40 | 75.90 | 66.00 |
Book Value Per Share | 0.28 | 0.13 | 1.59 | 4.23 | 5.34 |
Fiscal Year End for Gossamer Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 354 | 244 | 296 | 329 | 162 |
Receivables | 4 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 11 | 10 | 13 | 11 |
Total Current Assets | 371 | 255 | 307 | 341 | 173 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 1 |
Total Assets | 373 | 259 | 312 | 348 | 182 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 6 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 10 | 12 | 12 | 12 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 27 | 24 | 34 | 29 | 26 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 17 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 45 | 36 | 52 | 42 | 40 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 197 | 197 | 197 | 196 | 196 |
Long-Term Debt | 0 | 0 | 1 | 4 | 6 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 50 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 292 | 233 | 249 | 243 | 245 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,287 | 1,281 | 1,275 | 1,269 | 1,062 |
Retained Earnings | -1,205 | -1,254 | -1,212 | -1,164 | -1,124 |
Other Equity | -1 | -1 | 0 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 82 | 27 | 63 | 105 | -63 |
Total Liabilities & Shareholder's Equity | 373 | 259 | 312 | 348 | 182 |
Total Common Equity | 82 | 27 | 63 | 105 | -63 |
Shares Outstanding | 226.20 | 226.20 | 225.40 | 225.30 | 95.40 |
Book Value Per Share | 0.36 | 0.12 | 0.28 | 0.46 | -0.66 |